Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 14/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937114 | 1.00 | SCN5A (0.46) | SCN5ASCN1ASCN2ANR1H4IDH1 | |
| SCHEMBL15787102 | 0.89 | SCN5A (0.48) | SCN5ASCN1ASCN2A | |
| SCHEMBL12909266 | 0.89 | ALOX5 (0.36) | SCN5ANR1H4ADORA3 | |
| SCHEMBL15787103 | 0.89 | SCN5A (0.48) | SCN5ASCN1ASCN2A | |
| SCHEMBL938366 | 0.80 | SCN5A (0.46) | SCN5ASCN1ASCN2AADORA3 | |
| SCHEMBL12945164 | 0.76 | SCN5A (0.46) | SCN5ASCN1ASCN2AIDH1 | |
| SCHEMBL937849 | 0.75 | SCN5A (0.58) | SCN5ASCN1ASCN2A | |
| SCHEMBL935933 | 0.74 | SCN5A (0.54) | SCN5ASCN1ASCN2A | |
| SCHEMBL938365 | 0.74 | SCN5A (0.46) | SCN5ASCN1ASCN2AADORA3 | |
| SCHEMBL1160640 | 0.74 | SCN5A (0.44) | SCN5ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | PRAXIS PRECISION MEDICINES, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2018098491-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8754103-B2 | — | — | 2014-06-17 | — | — | US | disclosed |
| US-8754103-B2 | — | — | 2014-06-17 | — | — | US | disclosed |
| WO-2011014462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | SCN5A 52/4885SCN1A 55/4885SCN2A 72/4885 |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | SCN5A 52/4885SCN1A 55/4885SCN2A 72/4885 |
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | SCN1A, SCN3A, SCN2A | SCN5A 7/4885SCN1A 1/4885SCN2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.